¡@ªü¯÷®üÀq¯g¤§Å@²z

 

¡@¡@¥H¤U¤å³¹¬°³Í±ÛÂå°|Å@²z®v¼B¨q¯]¤Î¿c¬ü¬X¦b°ªÂ寫¸g¤º¬ì¯f©Ð¶i­×, ©Ò§@ªº¶i­×³ø§i ¸g¦o­Ì¦P·N¶K¥X°Ñ¦Ò, ª©ÅvÄÝ­ì§@ªÌ¡C­ì¤å¤w¸g³¯¶¶³Ó±Ð±Â§@¯«¸g¾Ç¤è­±¤§­×¹¢¡C

ªü¯÷®üÀq«¬¥¢´¼¯g Dementia of the Alzheimer's Type (DAT)

¤@. «e¨¥: ªü¯÷®üÀq«¬¥¢´¼¯g­^¤å¦WºÙdementia of the Alzheimer's Type (DAT)¡A¬OÄÝ©ó ¥¢´¼¯g¨ä¤¤¤§¤@¶µ¯e¯f, ¦b¥xÆWµo¥Í²v¦û¥¢´¼¯g¬Û¹ï¤§µo¥Í²v36% (Liu & Lin, et al)¡Cªü¯÷®üÀq«¬¥¢´¼¯g¬O¤@ºØ°h¤Æªº¸£¯e¯f¡M¥¦©Ò³y¦¨ªºÃ¨§b¤j¦h¬O¤£¥i«ì´_ ªº¡C¥Ø«e¨ä¯f¦]»PªvÀø©|¦b¬ã¨s¤¤¡M¦b¬ü°ê¡M¦]¤j³¡¤À¥¢´¼¯gªº­Ó®×³£¬O¥Ñªü¯÷ ®üÀq«¬¥¢´¼¯g³y¦¨ªº¡M¨ä¤¤¥u¦³¤Ö©ó10%ªº±wªÌ·|´_­ì¡M¥B«eÁ`²Î¹p®Ú¥ý¥Í³Q¶E Â_¿©±w¦¹¯g¡M¬G¤Þ°_¥þ²y¦U¬Éªº­«µø¡C

¤G. ©w¸q: ¬O¤@ºØ°h¤Æ©Êªº¥¢´¼¯g¡M±Æ°£¦hµo©Ê¸£±ð¶ë¥¢´¼¯g(multi-infarction dementia, MID)¡N¼~Æ{µ¥¨ä¥L³y¦¨¥¢´¼ªº­ì¦]¡M«h¥i¶EÂ_¤j¸£°h¤Æ©ÊªºDAT¡C³q±`¦³³vº¥ ªº°O¾Ð¤O¡N»{ª¾¥\¯à¡N»y¨¥¡N§PÂ_¤O¤Î¦Û§Ú·ÓÅU¯à¤O¯Ê·l¡C

¤T. ¯f²z¤Î¾É¦]: Äjº©©Ê¤j¸£µäÁY¡M(1). ¤j¸£¥Ö½è¡N°ò©³®Ö¡NÂÅ´³ªº¯«¸g²Ó­M´î¤Ö¡C(2). ¤j¸£ ¥Ö½è¦³Ãþ¾ý¯»´³¡M©PÃ䬰°h¤Æªº¯«¸g²Ó­M¬ð°_¡C(3). ®ü°¨¦^³B¯«¸g²Ó­M¤§Áû²ÉªÅ ªw°h¤Æ¡C(4). ¯«¸gÅÖºûÂO¦b¹q¤lÅã·LÃè¤U¥i¨£§áµ²¦¨¤@²ÓºÞ¡C(5). ¥Í¤Æ³¡¤À·|µo ²{¯«¸g¶Ç¾É¨t²Î¨ü·l¡M¤]´N¬O¤AñQÁxÆP(acetylcholine)ªº¤ä°t¦³²§±`²{¶H¡C ­P¯f¾÷Âà©|¤£©ú½T¡M

¦ý¨ä¬ÛÃö¦]¯À¦p¤U:

(1). ¿©±w²vÀHµÛ¦~ÄÖ¼W¥[¦Ó¼W¥[¡C (2). °ò¦]¤WÅܤơM²Ä19¹ï¬V¦âÅé¤W¤§¨ã¦³APOE 4 haplotypeªÌ¡M±ß´Á±oDATªº ¾÷²v¸û°ª¡C(3). ±w­ð¤ó¯gªÌ¨ä21¹ï¬V¦âÅé²§±`©Î²Ä1¡N²Ä14¹ï¬V¦âÅ骺²§±`¡M ¦­´Á±oDAT¾÷²v¸û°ª¡M¥B¦³®a±Ú¿ò¶Ç¶É¦V(Plassman & Breitner, 1997)¡C(4). ¯f¬r ·P¬V¡NÀô¹Ò¦Ã¬V¡NÀY³¡·l¶Ë¤]¥i¯à³y¦¨¦¹¯f¯g¡C

¥|. Á{§Éªí¼x: ¦­´ÁªºDAT±`¦³³¡¤À°O¾Ð¤O¨ü¼vÅT¡M«Ü¤Ö¦³»y¨¥¤Wªº»Ùê¡M³¡¤À±wªÌ·|¦ñ ÀHµÛ¶åı¤Wªº¯Ê·l¡M¦ý±`³Q©¿²¤¡Cªñ¦~¨Ó¬ã¨s«ü¥X³o¨Ç­Ó®×¤w¦³ù®¸­µäÁY¤Î¤j¸£ ¥Ö½è³¡¤Àªº¥NÁ»Ùê¡M¦ý³o¼Ëªº¯Ê·l¨Ã¥¼³Q½T©w»P¯gª¬¬ÛÃö¡M¦]³\¦h±wªÌ¤£·|¦³ §¹¥þ¥¢´¼¡C¤j³¡¥÷±wªÌ¦b¯f¾ú¤WÅã¥Üªø´Áªº°O¾Ð¤O¯Ê·l¤Î¯à¤O¤£¨¬¡NªÀ·|¤ä«ù¨t ²Î¤£¨Î¡N»Ý¾AÀ³¿W¥ß¥Í¬¡¡C DAT±wªÌ¨ä¯fµ{¦Ûµo¯f¨ì¦º¤`¬ù8-10¦~¡M

¡@¡@®Ú¾ÚÁ{§Éªí¼x¤j²¤¥i¤À¬°¤T­Ó¶¥ ¬q, ¥­§¡¨C¦~±wªÌ¨äMMSE(Mini-Mental State Examination)¤À¼Æ¤U­°3-4¤À¡M¦pªG ¤À¼ÆÆJ­°«h¥i¯à¦ñÀH¦³¨ä¥L¯e¯f¡M¨Ò¦p¡G¡@¼~Æ{¯g¡N¤º¬ì¯e¯f¡N¸£¦åºÞ¯fÅÜ¡N¸£ ¤ô¸~¡N¤Î¥NÁ¡NÀç¾i¡N¤º¤Àªc¥¢½Õ¡CªvÀøªÌ»Ý¥ý³B²z¨ä¥L³y¦¨¥¢´¼¯g¤§¥i°f©Ê¯e ¯f¡G

¡@¡@²Ä¤@´Á (¦­´Á) (Stage I, Early): MMSE=20-30¡C³Ìªìµo¯f2-3¦~¡M±wªÌ¦³µu´Á°O ¾Ð¤OÅÜ®t¡N»´·Lªºªø´Á°O¾Ð¤O¯Ê·l¡NµøÄ±ªÅ¶¡§PÂ_¯à¤O¥¢½Õ¡N»´«×ªº»y¨¥»Ùê¡N ¤ß¤£¦b²j¥B°¸º¸¦³Ä¼°Ê¤£¦wªº²{¶H¡C *¦b¦¹®É´Á»P¨ä¥L¯e¯fªº°Ï¿ë¤èªk ¦]¼~Æ{¯g±wªÌ±`¦³°O¾Ð¤O¤£¨Î¤Îª`·N¤OµLªk¶°¤¤¤§»{ª¾»Ùê¡M¦]¦¹¦b½T¥ß DAT¶EÂ_¤§«e¡M¼~Æ{¯gªºªvÀø¬O¥²»Ýªº¡C¥t¥~¤@¨Ç¦³ÃB¸­¤Îù®¸­¯fÅܪº±wªÌ·| ¦³¸ûÄY­«ªº»{ª¾»Ùê¡C ¸£¤ô¸~¤Þ°_ªºÃB¸­¤Î³»¸­¥¢´¼¯g·|¦³¨BºA¤íí¤Î¥¢¸T¡M³o¨Ç¯gª¬¥u·|µo¥Í¦b DATªº¥½´Á¡C ®w¸ë¤ó¯g(Creutzfeldt-Jacob disease)¤@¶}©l¯gª¬¤]¬O°O¾Ð³à¥¢¡M¦ý«Ü§Ö¦a·|¦b µuµu´X¬P´Á©Î´X­Ó¤ë¤§¤º¶i¦æ¦Ü§¹¥þ¥¢´¼¡M­Y¬O¦ñÀH¦³¹B°Ê¥¢½Õªº±wªÌ¨ä¸£¹q¹Ï (EEG)·|¦³¬ðµMªºÅܤơM³o¬O¥i¥H»PDAT°Ï¤Àªº¡C Äjº©©ÊLewy Body disease¦­´Á·|¦³À@Åé¥~®|¯g­Ô¸s(EPS)¤Î¤Ûıªº²£¥Í¡M¨ä À@Åé¥~®|¯g­Ô¸s¯gª¬¶i¦æ¬O¸û§Ö³tªº¡C ¦b¦¹®É´Á¡MÁöµM¶ÝºÎ¦³®É¤]±`¨£¡MÃĪ«¤Þ°_ªººC©Ê¤¤¬r¤]»Ý­n³Q¦Ò¶q¡M¥HÁ× §K©µ»~ªvÀø¡C¦åºÞ©Ê¥¢´¼¯g(vascular dementia)¡B°sÅ}¡B»PDAT¦b¦­´Á¬O®e©ö³Q ²V²c¡M¦¹®É¥i¥ÎHachinski scale (Pantoni & Inzitari, 1983)¤Îªñ¦~¨Óªº¶EÂ_¼Ð·Ç¨ÓŲ §O¶EÂ_¡C

¡@¡@²Ä¤G´Á(¤¤´Á) (Stage II, Middle): MMSE=10-19¡C¦b±w¯f3-4¦~«á¡M±wªÌ¦³ÄY­« ªº°O¾Ð¤O¯Ê·l¡MªÅ¶¡©w¦V·P®t¡N»¡¸Ü¨S¦³·N¸q¦ý¬yºZ¡N­pºâ¯à¤O¤£¨Î¡N»{ª¾»Ùê¡N ¹ï¨Æª«ºz¤£Ãö¤ß¡Nļ°Ê¥B§¤¥ß¤£¦w¡N¿â¨B¡NµLªk¨Ì«ü¥O°µ°Ê§@¥B°¸¦³¦k·Q¡C ¦¹¶¥¬q¯f±w¬ù¦³20%ªº¤H¦ñ¦³¼~Æ{¯gª¬¡M40%¦³¦k·Q¡N¤Ûı¡N¥B±`¦³ºÎ¯v«¬ºA ¯¿¶Ã¡Q¦³¨Ç¤H¬Æ¦Ü¦³§ðÀ»¦æ¬°¤Î¥|³B¹C¿º¡C¦]¦¹¦b¬dı­Ó®×¦³»{ª¾°h¤Æ²{¶H®É¡M §YÀ³¦Ò¼{¥H§Ü¼~Æ{¾¯¤Î¯«¸g¬ìÃĪ«ªvÀø¡C­Y¯f¤H¹ïÃĪ«²£¥ÍÀ@Åé¥~®|¯g­Ô¸sªº°Æ §@¥Î®É¡M»Ýµ¹¤©¯S§O·ÓÅ@¡C¯f±w¨ä¤é±`¥Í¬¡¤Î¸gÀÙ¬O»Ý­n¨ó§Uªº¡Q¦Ó¨ä¤@°_¥X²{ ªº¨ä¥L¯f¯g¡M¦p©I§l¹D¡Nªc§¿¹D·P¬V¡NÀç¾i¤£¨}¤ÎªÍª¢¡MÀ³³Qµo²{¤ÎªvÀø¡C¥t¥~¡M ¯f¤Hªº©Ò¦³ÃĪ«»Ýª`·N¬O§_·|³y¦¨Â¤¦k©Î¯f±¡´c¤Æ¡C

¡@¡@²Ä¤T´Á(«á´Á) (Stage III, Late): MMSE=0-9¡C¯f±w§e²{·¥®tªº»{ª¾¥\¯à¡N¨BºA©ú Å㤣í¡NªÏÅ黸µw¥BùÌÁY¡N¨Ã¦³¤j¤p«K¥¢¸T¡Q±`¨£§¿Àx¯d¤Î§¿¹D·P¬V¡C­Ó®×»Ý³Q µû¦ô¨ä¥Í¬¡¦w±Æ¬O§_«ê·í¡M¥i«ØÄ³°µ¦³­p¹ºªº¨Ò¦æ¬¡°Ê¡C¤j¬ù¥u¦³5-10%ªº¯f±w ·|¬¡°Ê¹L«×¡M¦¹®É­Y¨Ï¥Î¬ù§ô¤ÎÂí©w¾¯·|»s³y§óÄY­«ªº¦æ¬°°ÝÃD¡C

¤­. ¶EÂ_µû¦ô: ºë¯«¬ìDSM-IVªº¶EÂ_·Ç«h¬O¨Ì¾ÚWashington University model¡M¦¹·Ç«h¹ï ©ó¤F¸ÑDATªºÁ{§É¹B¥Î¡N¬ã¨s¤Îµo®i¬O¬Û·í¦³À°§Uªº¡CDAT¥u¯à¥Ñ¯f²z²Õ´ ½T»{¡M¦b¯f±w¬¡µÛ®É¬O«ÜÃø°µ¯f²zÀˬdªº¡M®Ú¾Ú¬ã¨s·í­Ó®×¥HDSM-IV¶EÂ_¥X DAT®É¡M¨ä¦º¤`«á¦³85-90%ªº¸£²Õ´Àˬd¥i½T»{¬°DAT¡M¦]¦¹DSM-IV¨ã¦³ °ª«×ªº·Ç½T©Ê¡C¤j³¡¤ÀDAT­Ó®×¨ä¸£³¡¬O»P¥¿±`¦Ñ¦~¤H«D±`¤£¦Pªº¡M¤£¹³¨ä¥L ºë¯«¯e±w¡MDAT¬O»P¸Ñ­å¯f²z¬ÛÃöªº¡C l DAT¤§¶EÂ_·Ç«h (DSM-IV) (APA, 1994)

A. ¦h­«ªº»{ª¾¯Ê·l(¥H¤U¦Ü¤Ö¨â¶µ):

1. °O¾Ð¤O¯Ê·l(µLªk¾Ç²ß·sª¾©ÎµLªk¦^¾Ð¥ý«e©Ò¾Ç)¡C 2. »{ª¾»Ùê(¦Ü¤Ö¤@¶µ)¡C a. ¥¢»y¯g¡C b. ¥¢¥Î¯g¡C c. »{ÃѤ£¯à¡C d. ­p¹º¡N²Õ´¡N±Æ§Ç¤Î©â¶H«ä¦Òªº¥\¯à°õ¦æ»Ùê¡C

B. ªÀ¥æ¤Î¤u§@¯à¤O©úÅã¤U­°¡C

C. º¥º¥´c¤Æ¥B¦³«ùÄòªº»{ª¾°I°h¡C

D. ¨Ã«D¥Ñ¤U¦C±¡ªp¤Þ°_ªº»{ª¾»Ùê:

1. ¦]¤¤¼Ï¯«¸g¨t²Î¤Þ°_ªº°O¾Ð©M»{ª¾¯Ê·l(¦p: ¸£¤¤­·¡B©¬ª÷´Ë¤ó¯f¡Bº~Ëo ¹y¯f(Huntington's disease), µw½¤¤U¦å¸~¡B¥¿±`À£¤ô¸£¯g(normal-pressure hydrocephalus¡B¸£½Fµ¥)¡C 2. ¥i¹îıªº¨t²Î©Ê¯e¯f©Ò³y¦¨ªº¥¢´¼(¦p ¥Òª¬¸¢¾÷¯à§C¤U¡Bºû¥L©R B12©Î ¸­»Ä¯Ê¥F¯g¡Bniacin¯Ê¥F¯g¡B°ª¦å¶t¯g¡B¯«¸g©Ê±ö¬r¡BHIV·P¬V¡C 3. ª«½èÀݥΤް_ªº¥¢´¼¡C

E. ¨Ã«D¤¦k¯gª¬?F. ¨Ã«DAxis I¶EÂ_¤Þ°_ªººë¯«²V¶Ã©Ê¯e¯f(¦p: major depression disorder, schizophrenia)¡C l ¶EÂ_¤ÀÃþ¾ð: ¥i¨Ì·Ó¤U¦C¨BÆJ°µÅ²§O¶EÂ_: 1. ¬O§_¥X²{»{ª¾¥\¯à¯Ê·l? ®Ú¾Ú­Ó®×¦~Ä֤αШ|µ{«×MMSE°¾§C¡C MMSE¤À¼Æ¤p©ó27»Ý¸ÑÄÀ¦¨¦]¡C 2. ¬O§_»{ª¾¥\¯à´c¤Æ? ­Y¨Ã«D¤ñ¥H«e®t¡M«h¬°´¼¯à»Ùê¡C 3. ·NÃѲM¿ô¶Ü?ĵı©Ê°ª¶Ü? ­Y¤£²M¿ô¡Nĵı©Ê®t«h¬Oĸ¿Î(delirium)¡C 4. ¬O§_¦³¦h­«·l¶Ë¡M©Î¥u¦³ÅãµÛªº³æ¤@¥\¯à¯Ê·l? °²¦p¦³¦h­«·l¶Ë¡M«h±Æ°£¬O°O¾Ð»Ùê¡N¥¢»y¯g¡N¹B°Ê¤£¯à¡N»{ÃѤ£¯à…µ ¥¥\¯à¯Ê·l¡C 5. ¬O¨È«æ©Ê©ÎºC©Êªº? ¦pªG¬O¨È«æ©Êªº¡M«h´M§ä³Ì¥~¨Óªº¥i°f©Ê­ì¦]¡M¨Ò¦p: ¸~½F¡NºC©Ê¸£½¤ ¸£ª¢¡NAIDS¥¢´¼¡N¥Òª¬¸¢¥\¯à§C¤U¡NCushing's Syndrome¡NÀç¾i¥¢½Õ¡N ºC©ÊÃĪ«¤¤¬r¡N«Âº¸´Ë¤ó¯f¡N®w¸ë¤ó¯g¥H¤Î¨ä¥L¸£¯«¸g¯fÅÜ¡M¨Ò¦p: Gerstman-Scheinker-Strausler Disease¡C 6. ¬Oº¥¶i´c¤Æ©Î¬ðµM¶¥¬q©Ê´c¤Æ? ¦pªG¬O¬ðµM¸ó¶¥¬q©Ê´c¤Æ¡M«h¦Ò¼{¦åºÞ©Ê¥¢´¼¯g¡M©Î¬O¦³¥Ö½è¤U±ð¶ëªº Cerebral Autosomal Dominant Arteriopathy¸£¥Ö½è¯f(CADASIL)¡C 7. ¬O§_¦³¤j¸£¥Ö½è¯gª¬(¨Ò¦p: ÄY­«°O¾Ð´î°h¡N»y¨¥»Ùê¡N¨ã¦³§¹¾ãªº·L²Ó ¹B°Ê¥\¯à)¡M©Î¦³¥Ö½è¤U¯gª¬(¦p: ¦³¹B°Ê»ÙꪺÄY­«ª`·N¤O¯Ê·l)¡C°²¦p ¬O¡M¥Ö½è¤U¯gª¬¡M«h¦Ò¼{: ¸~½F¡N¸£³Ð¶Ë¡N¦åºÞ©Ê¥¢´¼¯g¡NÃB¸­¥¢´¼¯g ¯g­Ô¸s¡Nº~Ëo¹y¯f¡N©¬ª÷´Ë¤ó¯g¡NProgressive Supranuclear Palsy¡N Dementia with Spastic Paraplegia¡NMyoclonic Epilepsy¡NCerebrocereballer Degeneration¡NCerebral Basal Ganglia Degeneration¡NSpongiform Encephalopathies¡NDemyelinating Diseases¡NProgressive Multi-Focal Leukoencephalopathy¡NMarachiafava-Bignani Disease¡NLipid Storage Diseases¡C 8. ¦pªG¬O¤j¸£¥Ö½è¯gª¬¡M«h¦Ò¼{²Ä¤@¯gª¬¬O§_¬°»{ª¾¥\¯à¯Ê·l? ­Y«D»{ª¾¯Ê·l«h¥i¯à¬OÃB¸­¥¢´¼¯g¤ÎPick's disease. 9. ¬O§_¦³EPS? ¦pªG¦³¡M«h¦Ò¼{¬OLewy Body dementia©Î©¬ª÷´Ë¤ó¯g¡C¦pªG¨S¦³¡M«h¦Ò ¼{DAT. Á`¦Ó¨¥¤§¡M¤U­±ªºªk«h¥i¥H¥Î¨Ó¦Ò¶q­Ó®×ªº¶EÂ_: l ±q­Ó®×ªº¥D¶D¡Mµû¦ô¯Ê·l¤Î¨ä´c¤Æªº³t«×¡C l ­Y¦³´c¤Æ«hµû¦ô·NÃѪ¬ªp¡C l ¦pªG¬O²M¿ôªº¡M«hµû©w¯gª¬¬O³¡¤Àªº©Î¾ãÅ骺¡C l ­Y¬O¾ãÅ骺¡M«hµû¦ô¬O¥Ö½è©Î¥Ö½è¤U¯gª¬¡C .¥H¤Wªº«ä¦Òªk«h¬O°w¹ï·í­Ó®×¥u¦³¤@ºØ·l¶Ë¦Ó°²³]ªº¡M¨Æ¹ê¤W¡M«Ü¦hªº­Ó®×¬O ¥Ñ©ó¦hµo©Ê¥¢½Õ³y¦¨ªº¡C©¬ª÷´Ë¤ó¯g¬O±`»PDAT²V²cªº¡M¦åºÞ©Ê¥¢´¼¯g¤]¬O³o ¼Ë¡C­Ó®×±w¦³¥¢´¼¯g³q±`¬Ý°_¨Ó·|¹³¬O¤¦k©Îªq³à¡C¦¹®É¡M»Ý­n¾ãÅé©Êªº¬ã°Q¡Q ¦b¶EÂ_½T¥ß¤§«e¡M¥²¶·±q¥i°fªº¥ýªvÀø¡C¦Ñ¦~¤H¤¤°sÅ}¤Î¥¢´¼¯g¤§¶¡ªºÃö«Y¤´¤£ ©ú½T¡M¦ý¦b³o¦~ÄÖ¼h¤¤¡M°sºë¤£±`¬O¾É¦]¡C

¤». ªvÀø: ±q´î»´¯gª¬°µ³B²z¡M¥Ø«e¨S¦³ªv¡¤èªk¡C l ÃĪ«: 1. ¤TÀô§ÜÆ{¾¯¤ÎHalopiridol¥i±±¨îļ°Ê¤Î¤Ûı¡C 2. Tacrine (Cognex)¤Îaricept³Q»{¬°¥i§ïµ½»{ª¾¥\¯à¤Î¥Í¬¡«~½è¡C¤£¹Lªñ¨â ¦~¨Ó¥Ñ©ó¨ä¨x¬r©Ê¡Atacrine¤w³Qaricept©Ò¨ú¥N¡C l Å@²zª`·N¨Æ¶µ: ·íDAT­Ó®×½Õ¾A¥¢½Õ®É¡M·|µo¥Í«æ©Ê¬ðµo©Ê¤ÏÀ³¡M¯S¼x¥]¬Aļ°Ê¤£¦w¡N¥¢ ¯v¡M³o¥i¯à¬OÂå°|­¯¥ÍÀô¹Ò³y¦¨ªº¼vÅT¡M¦æ¬°¤W¥i¥Hhaloperidol(Haldol) 2-5mg PO©ÎIM; lorazepam(Ativan) 5 mg PO©Î1 mg IM; ­Y¦ñ¦³¼~Æ{¥i¨Ï¥Î nortriptyline (Pamelor)©Îtrazodone (Mesyrel); antihistamines; chloral hydrate(Noctec); ºû«ùÀô¹ÒªºÂ²³æ¡N¦wÀR¡N¤Î¥Rº¡¬X©Mªº¥ú½u¡C l ©~®a¤p±`ÃÑ: *·í¬ðµo©Ê¤ÏÀ³¤Î¥¢¯vµo¥Í®É¡M¥i¥Î»´­µ¼Ö¨Ó½w¸Ñ¡C *Åý­Ó®×¬ïÀ¹¨¾¨«¥¢ªºÄµ¥Ü¾¹, ¨Ã´£¨Ñ­«½Æ·P©x¡NIJı¡N©ÎÅé¦ìı¨ë¿E¡M¦p: ­µ ¼Ö¤Î·nÂ\¡C

¤C. ¨Öµo¯g: 1. ·P¬V: ¥]¬A©I§l¹D¤Îªc§¿¹D¡C 2. ¥Ñ©ó¯Ê¥F¯fÃÑ·P¡N¤Ûı©Î²V¶Ã©Ò³y¦¨ªº·l¶Ë¡C 3. ¦]¦Y¶º®Éª`·N¤O¤£¶°¤¤¾É­PªºÀç¾i¥¢½Õ¤Î¦Ù¾j©Î¯Ê¥F·Ç³Æ­¹ª«ªº¯à¤O¡C

¤K. Å@²zµû¦ô: 1. ¹ï©ó©w¦V·P¡N¯fÃÑ·P¡N©â¶H«ä¦Ò¤Î°O¾Ð¤Oªº»{ª¾¥\¯àµû¦ô¡C 2. µû¦ô¨­ÅéÀç¾i¤ÎÅé²G¹q¸Ñ½è¡NÅé­«¡N¥Ö½§ª¬ªp¤Î¦Y¶º²ßºD¡C 3. µû¦ô¹B°Ê¯à¤O¡N¦Ù¦×±j«×¡N¦Ù¦×±i¤O¤Î¼u©Ê¡C

¤E. Å@²z¶EÂ_: A. «ä¦Ò¹Lµ{Åܲ§/»P¯e¯f³y¦¨ªº¥Í²zÅܤƬÛÃö¡C B. °ª¦MÀI©Ê·l¶Ë/¦]»{ª¾¯à¤Oªº³à¥¢¡C C. ªÀ¥æ¤¬°Ê»Ùê/»PÀô¹Òªº²z¸Ñ¯à¤O¤U­°¡C D. ºÎ¯v«¬ºA¯¿¶Ã/¦¸µo©ó¯e¯f¶i®i¡C E. Àç¾iª¬ªp§ïÅÜ(¤Ö©ó¨­Åé©Ò»Ý)/»P°O¾Ð¤O³à¥¢¤Î­p¹º¯à¤O§ïÅܬÛÃö¡C F. ·ÓÅUªÌ¨¤¦âºò±i/»P­Ó®×¯e¯f¶i®i²£¥Íªº¦æ¬°¤Î¥Í²z»Ý¨D¬ÛÃö¡C

¤Q. Å@²z±¹¬I: A. ¥[±j»{ª¾¥\¯à 1. Àô¹Ò²¤Æ: ´î¤Ö¾¸­µ¤ÎªÀ·|¤¬°Ê¨ì­Ó®×¥i¥H§Ô¨üªºµ{«×¡C 2. ºû«ù¤£Åܪº¨Ò¦æ§@®§¡MÅý¯f¤H´î¤Ö¿ï¾Üªº¶µ¥Ø¡M¨Ï¥Î¹Ï¤ù¥H¼W¥[¯f ¤Hªº°Ï¿ë¯à¤O¡C 3. ¦b­Ó®×±`¬Ý¨ìªº¦a¤è¸m©ñ¤j«¬¤ë¾ä¤Î®ÉÄÁ¥H¼W¥[¨ä¹ï¤H¡N®É¡N¦aªº ©w¦V·P¡C 4. ¨Ï¥Î°O¨Æ¤Î¥iŪªº«ü¥O¨Ó´£¿ô¨C¤é¬¡°Ê¡C 5. ºû«ù»P¥L¤Hªº«ùÄò¤¬°Ê¨ÃºCºC¦a¤¶²Ð»{ÃÑ·s¤H¡C B. ¹w¨¾¨ü¶Ë 1. ¾¨¶qÁ×§K¬ù§ô¯f¤H¡M¥²­n®É±K¤ÁÆ[¹î­Ó®×¡C 2. ´£¨Ñ¥R¨¬ªº¿O¥ú¥HÁ×§K¹ïÀô¹Òªº»~§P¡C 3. ²¾°£©Ð¶¡¤º¤£¶·­nªº®a¨ã¤Î³]³Æ¡C 4. ´£¨Ñ¿ëÃѨ­¥÷¤Î¯e¯fªº¦WµP©Î¤â°é¡C 5. ½T©w­Ó®×¬ïµÛ¤£·Æ¥B©ö¬ï²æªº¾c¤l©Î©ì¾c¡C *©~®a·ÓÅ@¤p±`ÃÑ: l ´£¿ô®aÄÝ·í­Ó®×¦æ¬°¤ÏÀ³°h¤Æ®É¦b®a¤¤©Ò¥i¯àµo¥Íªº¦MÀI¡C l ¹ªÀy®aÄݱN¼ö¤ô±±·Å¨t²Î½Õ­°¡N±N¥Ë´µÄl¤Î¹q¾¹¶}Ãö³]©w¦w¥þÂê ±N¤õ®ã¤Î¥´¤õ¾÷¦¬§´¡N©Î±N¤u¨ã¤Î¨ä¥L¦MÀIª««~¦¬°_¡C C. ºû«ùªÀ¥æ¤¬°Ê 1. ¹ªÀy®aÄÝ»P¯f¤Hºû«ù¦³·N¸qªº¤¬°Ê¡C 2. ¦V®aÄݸÑÄÀ¾¨ºÞ»P­Ó®×ªº¯u¥¿¤¬°Ê¬O¦³­­ªº¡M¥L­Ìªº±´µø¬O¦³À°§U ªº¡C 3. ­n¨D®aÄݬ°¯f¤H±a¨Ó¦³·N¸qªºª««~¡C D. ½T©w¦³¥R¤Àªº¥ð®§ 1. µ¹¤©§Üºë¯«¯fÃĪ«¥H³B²zļ°Ê¡C 2. ´£¨Ñ¤À¬q¦¡ªº¬¡°Ê¥Hµo¬ªºë¤O¡C 3. ºû«ù¥¿±`ªººÎ¯v²ßºD¥B«ö®É¤W§ÉºÎı¡C a. «O«ù¤@©wªº¤W§É®É¶¡¡C b. ºÎı«eÅý­Ó®×´«¤WµÎ¾AªººÎ¦ç¡C c. ¤¹³\·Ç³ÆºÎıªº¬¡°Ê¡M¦p: ¦YÂI¤ß¡N³ÜµL©@°Ø¦]ªº¶¼®Æ¡NÅ¥­µ ¼Ö¡N©Î¬èë¡C 4. ºû«ù»´ÃP¤Î¦wÀRªºÀô¹Ò¥HÁ×§K²V¶Ã¤Îļ°Ê¡C E. ºû«ù¾A·íªºÀç¾i 1. ´£¨Ñ¼ô±xªº­¹ª«¡C 2. ¤Ö¶q¦hÀ\¡M°¸º¸µ¹¤©ÂI¤ß¡C 3. ´£¨Ñ«K©ó¨ú¥Îªº­¹ª«¡C 4. ´£¨Ñ°ª¼ö¶q¡N°ªÅÖºû­¹ª«¡C 5. ¹ªÀyÄá¨ú²GÅé¡C 6. ½T©w¤ú¾¦Ã­©T¨Ã¹ªÀyºû«ù¤ú¾¦«O°·²ßºD¡C 7. ¨C¶g½SÅé­«¡C F. ·ÓÅUªÌªº¤ä«ù 1. ¹ªÀy·ÓÅUªÌªí¹F¤º¤ß¯u¹ê·P¨ü¡C 2. ¹ªÀy·ÓÅUªÌºû«ù¨­Åé°·±d¤Î±¡ºüí©w¡C 3. ±j½Õ©w´Áªº©ñÃP®É¶¡¤Î³Ý®§·ÓÅ@(Respite Care)ªº»Ý­n¡C 4. ¨ó§U·ÓÅUªÌ§Q¥Î¸ê·½¡M¦p: ªÀ°Ï©Î©v±Ð¹ÎÅé¡NªÀªA¬¡°Ê¡N©Î¥HÂå°| µ²¦Xªº¤ä«ù¹ÎÅé¡C 5. µû¦ô·ÓÅUªÌÀ£¤Oµ{«×¡M¥²­n®ÉÂश¿Ô°Ó¡C 6. ¦b®aÄݨM©w°e­Ó®×¤JÅ@²z¤§®a®Éµ¹¤©¤ß²z¤ä«ù¡C

¤Q¤@. ¯f¤H±Ð¨|¤Î°·±dºûÅ@ 1. ¹ªÀy»Ý­n¤Ö³¡¤À«ä¦Ò«o¦³­«½Æ°Ê§@ªº¹B¥Î¨­Å骺¬¡°Ê¡M¨Ò¦p: ¸õ»R¡N¬~ ¦ç¡N©Î§l¹Ð¡C 2. ±Ð¾É­Ó®×¤Î®aÄÝÁ×§K¨ë¿E©Ê­¹ª«¡M¦p: ©@°Ø¦]¡C 3. »P®aÄݰQ½×°]°È°ÝÃD¤Î°µ­«¤j¨M©w»PºÊÅ@ªÌ¦w±Æªº»Ý­n¤§«á¤~Åý­Ó®× ¯A¤J¹Lµ{¡C 4. ´£¨Ñ°Ñ»P¦P¾«©Ê¹ÎÅ骺¸ê°T¡M¨Ò¦p: ¥¢´¼¦Ñ¤H¨ó·|¡N·ÓÅUªÌ¨ó·|¡C

¤Q¤G. µû­È A. °Ñ»P¨C¤é¤é±`¥Í¬¡¬¡°Ê(ADLs)¡M¤£¥X²{²V¶Ã©Îļ°Ê¡C B. ¨S¦³¨ü¶Ë¡C C. »P®aÄݦ³¤¬°Ê¡C D. ±ß¤WºÎ¨¬¤»¤p®É¡M¨Ã¨C¤é¨â¦¸ªº¤@¤p®É¥ð®§®É¬q¡C E. ¨C¤é¤Ö¶qªº¤TÀ\¡N2-3¦¸ªºÂI¤ß¡Qºû«ù²z·QÅé­«¡M¨S¦³Åé­«¬y¥¢¡C F. ·ÓÅUªÌ¯à¦³¤@¶g¨â¦¸§Q¥Î³Ý®§·ÓÅ@ªº°O¿ý¡C

°Ñ¦Ò¸ê®Æ 1. ©P©¯¥Íµ¥¦XĶ(¥Á84)¡C·sÁ{§ÉÅ@²z¶EÂ_¡Cªìª©¤G¨ê¡CµØ§ö¡C 2. §d¶i¦w(¥Á85)¡C²Ä10³¹: ¥¢´¼¯g©M¨ä¥L°h¤Æ©Ê¯e¯f¡C°ò¦¯«¸g¾Ç¡Cªìª©¡C¦X °O¡Cpp: 154-157¡C 3. American Psychiatric Association (1994). Diagnostic and statistical manual o fundamental disorders(4th ed.). Washington, DC: American Psychiatric Association. 4. Ham RJ, Sloane PD. (1997). Chapter 17: Confuse, Dementia, and Delirium. Primary Care Geriatrics. 3ed, Mosby. Pp: 225. 5. Liu HC, Lin KN, Teng EL, Wang SJ, Fuh JL, Guo NW, Chou P, Hu HH. Chiang BN. (1995).Prevalence and subtypes of dementia in Taiwan: a community survey of 5,297 individuals. J Am Geriatr Soc, 43; 1-6. 6. Pantoni, L. & Inzitari, D. (1983). Hachinski's ischemic score and the diagnosis of vascular dementia: a review. Ital J Neurol Sci, 14, 539-546. 7. Plassman, B.L & Breitner, J.C.S. (1997). The genetics of dementia in late life. The Psychiatric Clinics of North America, 20(1), 59-76. 8. Nettina SM (1997) Chapter 13: Degenerative Disorder: Alzheimer's Disease. The Lippincott manual of nursing practice. Complete Nursing Reference on CD- ROM..Lippincott. -- * Origin: °ê¥ß¤¤¤s¤j¾Ç Formosa BBS * From: 163.15.163.24 [¤w³q¹L»{ÃÒ]